No labeled contraindications have been reported. Golimumab should not be administered concomitantly with a biologic class of disease-modifying antirheumatic drugs (DMARDs) or Janus kinase (Jak) inhibitors. The administration of live vaccines concurrently with golimumab is not recommended. The use of therapeutic infectious agents such as antibiotics and antiviral therapy with golimumab is also not advised.

Golimumab use in pregnancy may result in an increase of infections for up to 6 months in newborns. Infants exposed to golimumab in utero are advised not to receive any live vaccinations for up to 6 months following the mother's last golimumab treatment during pregnancy.